Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
CompuMed is a micro-cap healthcare IT services provider specializing in teleradiology and remote diagnostic interpretation services, primarily serving hospitals, imaging centers, and physician practices across the United States. The company operates a network of board-certified radiologists who provide remote reading services for X-rays, CT scans, MRIs, and other diagnostic imaging studies, competing in a fragmented market against larger players like RadNet and vRad (Mednax). Recent 61% annual stock appreciation reflects strong revenue growth (21.3% YoY) despite persistent operating losses, suggesting investor optimism about scaling toward profitability.
CompuMed generates revenue through per-study interpretation fees charged to healthcare facilities, typically ranging $15-75 per read depending on modality complexity (plain film X-rays at lower end, complex MRI/CT with contrast at higher end). The business model relies on variable radiologist contractor costs (estimated 40-50% of revenue) while maintaining fixed technology infrastructure and sales overhead. Gross margin of 47.4% indicates moderate pricing power constrained by competitive bidding for hospital contracts and reimbursement pressure. The company lacks significant economies of scale at current revenue levels (sub-$10M estimated annual run rate based on market cap), requiring volume growth to absorb fixed platform costs and achieve operating leverage.
New hospital or imaging center contract wins - each multi-year agreement can represent $500K-2M in annual recurring revenue
Radiologist network expansion and retention - ability to maintain 24/7 coverage across subspecialties (neuroradiology, musculoskeletal, cardiac) drives service quality and contract renewals
Operating margin trajectory toward breakeven - market is pricing in path to profitability as revenue scales past $12-15M threshold
Competitive threats from larger teleradiology consolidators (RadNet, vRad/Mednax) or AI-assisted reading platforms that could compress per-study pricing
Regulatory changes affecting telehealth reimbursement or cross-state medical licensing requirements for radiologists
AI-assisted diagnostic reading technology threatens to commoditize routine interpretation work (chest X-rays, bone fractures), potentially reducing per-study pricing by 30-50% for high-volume, low-complexity studies over 3-5 years as FDA-cleared algorithms gain adoption
Radiologist shortage in US may reverse as teleradiology enables international reading (Australia, Israel radiologists covering US night shifts), increasing contractor supply and compressing margins
Regulatory risk from state medical licensing requirements - any tightening of cross-state practice rules would limit radiologist network flexibility and increase credentialing costs
Large teleradiology consolidators (RadNet with $1.4B revenue, vRad/Mednax) can offer integrated imaging center + reading services bundles that CompuMed cannot match, limiting addressable market to smaller community hospitals
Hospital systems increasingly building in-house teleradiology capabilities using employed radiologists, reducing outsourcing demand particularly for high-margin subspecialty reads
Pricing pressure from group purchasing organizations (GPOs) that negotiate volume discounts for hospital members, compressing per-study fees by 15-25% versus direct contracts
Negative net income (-0.9% margin) and minimal operating cash flow create ongoing liquidity risk - current ratio of 2.04x provides 12-18 months runway at current burn rate, but sustained losses may require dilutive equity financing
Micro-cap illiquidity (sub-$10M market cap) limits access to institutional capital and creates refinancing risk if bridge financing is needed before achieving profitability
low - Healthcare utilization for diagnostic imaging is relatively non-discretionary, driven by acute care needs and chronic disease management rather than GDP growth. However, elective procedures (orthopedic imaging, preventive screenings) show modest cyclicality during recessions when patients delay non-urgent care. Hospital capital budgets for outsourced radiology services may tighten during economic stress, but existing contracts provide revenue stability.
Rising interest rates create modest headwinds through two channels: (1) higher discount rates compress valuation multiples for unprofitable growth companies, particularly micro-caps trading at 0.9x sales, and (2) hospital systems facing higher borrowing costs may scrutinize outsourced service contracts more aggressively during budget cycles. However, CompuMed's minimal debt (0.23x D/E) insulates it from direct financing cost increases. The primary rate impact is valuation compression rather than operational pressure.
Minimal direct credit exposure - revenue is derived from hospitals and imaging centers with stable payment histories, though Medicaid/Medicare reimbursement cuts could indirectly pressure customer budgets. Accounts receivable quality depends on hospital financial health, with potential DSO extension if healthcare systems face liquidity stress. The company's 2.04x current ratio provides cushion against customer payment delays.
momentum - The 61% one-year return and 54% three-month surge attract speculative retail traders betting on micro-cap turnaround story, with 21% revenue growth suggesting inflection toward scale. However, negative profitability and sub-$10M market cap exclude institutional investors due to liquidity constraints and risk management policies. The stock appeals to high-risk tolerance investors seeking asymmetric upside if the company reaches $15-20M revenue with positive EBITDA, potentially rerating from 0.9x sales to 2-3x on profitability proof.
high - Micro-cap healthcare IT stocks with minimal float exhibit 40-60% annualized volatility, driven by illiquid trading (wide bid-ask spreads), binary contract win/loss announcements, and quarterly earnings surprises on small revenue base. Beta likely exceeds 1.5x relative to healthcare sector, with single-day moves of 10-20% common on material news. Institutional absence amplifies retail sentiment swings.
